Are the ALHC share prices in the Form 4 exact or averages?

The reported prices are weighted-average prices for groups of trades. Footnotes explain shares were sold in multiple transactions within specific price ranges, and detailed trade-by-trade pricing is available upon request from Alignment Healthcare, any security holder, or SEC staff.

Alignment Healthcare (ALHC) CEO trust sells 298K shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Alignment Healthcare, Inc. director and CEO John E. Kao reported open-market sales of a total of 298,000 shares of Common Stock held indirectly through the JEK Trust, where he serves as trustee. The sales, executed under a Rule 10b5-1 plan adopted on 11/21/2025, were completed at weighted-average prices ranging from $20.26 to $21.49 per share across multiple trades. Following these transactions, the JEK Trust held 1,806,641 shares indirectly, and Kao also reported 1,784,868 shares held directly as of 04/10/2026.

Insider Trade Summary 10b5-1

Net Seller: 298,000 shares ($6,161,943)

Net Sell 4 txns

Insider KAO JOHN E

Role Chief Executive Officer

Sold 298,000 shs ($6.16M)

Type	Security	Shares	Price	Value
Sale	Common Stock	82,299	$20.798	$1.71M
Sale	Common Stock	201,900	$20.5807	$4.16M
Sale	Common Stock	13,801	$21.3785	$295K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,806,641 shares (Indirect, See Footnote); Common Stock — 1,784,868 shares (Direct)

Footnotes (1)

Date of Rule 10b5-1 plan adoption: 11/21/2025 The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.31 to $21.30. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $21.31 to $21.49. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.26 to $21.00. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Key Figures

Total shares sold: 298,000 shares Sale block 1: 82,299 shares at $20.798 Sale block 2: 201,900 shares at $20.5807 +4 more

7 metrics

Total shares sold 298,000 shares Open-market sales reported in this Form 4

Sale block 1 82,299 shares at $20.798 Common Stock sold on April 13, 2026

Sale block 2 201,900 shares at $20.5807 Common Stock sold on April 10, 2026

Sale block 3 13,801 shares at $21.3785 Common Stock sold on April 10, 2026

Indirect holdings after trades 1,806,641 shares JEK Trust balance after April 13, 2026 sales

Direct holdings reported 1,784,868 shares Direct Common Stock position as of April 10, 2026

Rule 10b5-1 plan date November 21, 2025 Adoption date of trading plan governing these sales

Key Terms

Rule 10b5-1 plan, weighted-average price, indirect ownership, trustee

4 terms

Rule 10b5-1 plan regulatory

"Date of Rule 10b5-1 plan adoption: 11/21/2025"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted-average price financial

"The reported price in column 4 is a weighted-average price."

indirect ownership financial

"ownership_type": "indirect""

trustee financial

"Represents securities held by JEK Trust... of which Mr. Kao is the trustee."

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

Form 4 Insider Transactions: What Each Field Means →

04/13/2026 - 06:37 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last)

(First)

(Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE

CALIFORNIA

92868

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/10/2026		S⁽¹⁾		201,900	D	$20.5807⁽²⁾	1,902,741	I	See Footnote⁽³⁾
Common Stock	04/10/2026		S⁽¹⁾		13,801	D	$21.3785⁽⁴⁾	1,888,940	I	See Footnote⁽³⁾
Common Stock	04/13/2026		S⁽¹⁾		82,299	D	$20.798⁽⁵⁾	1,806,641	I	See Footnote⁽³⁾
Common Stock								1,784,868	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 11/21/2025

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.31 to $21.30. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

4. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $21.31 to $21.49. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

5. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.26 to $21.00. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Alignment Healthcare (ALHC) CEO John E. Kao report in this Form 4?

John E. Kao reported planned open-market sales of 298,000 shares of Alignment Healthcare common stock held through the JEK Trust. These transactions were executed under a Rule 10b5-1 trading plan and disclosed as indirect sales by the trust where he is trustee.

How many Alignment Healthcare (ALHC) shares were sold and at what prices?

The filing shows total sales of 298,000 Alignment Healthcare common shares. Weighted-average sale prices ranged from about $20.26 to $21.49 per share, with trades executed in multiple transactions within these price ranges on April 10 and April 13, 2026.

Were the ALHC stock sales by the JEK Trust pre-planned under Rule 10b5-1?

Yes. The Form 4 notes a Rule 10b5-1 trading plan adopted on November 21, 2025. Sales reported in this filing were executed pursuant to that plan, indicating they were pre-scheduled rather than discretionary timing decisions by John E. Kao.

How many Alignment Healthcare (ALHC) shares does John E. Kao hold after these transactions?

After the reported sales, the JEK Trust held 1,806,641 Alignment Healthcare shares indirectly. Separately, John E. Kao reported 1,784,868 shares held directly as of April 10, 2026, reflecting a substantial continuing ownership position in the company’s common stock.

Who actually holds the sold Alignment Healthcare (ALHC) shares reported in this Form 4?

The shares were held by the JEK Trust dated February 8, 2021. John E. Kao is trustee of this trust, so the transactions are reported as indirect ownership changes rather than direct personal trades in his individual brokerage account.